Linked Life Data

12114417

Source:http://linkedlifedata.com/resource/pubmed/id/12114417

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2002-7-12
pubmed:abstractText
Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2167-76
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:12114417-Adolescent, pubmed-meshheading:12114417-Adult, pubmed-meshheading:12114417-Aged, pubmed-meshheading:12114417-Aged, 80 and over, pubmed-meshheading:12114417-Antineoplastic Agents, pubmed-meshheading:12114417-Bone Marrow, pubmed-meshheading:12114417-Cytogenetic Analysis, pubmed-meshheading:12114417-Enzyme Inhibitors, pubmed-meshheading:12114417-Female, pubmed-meshheading:12114417-Follow-Up Studies, pubmed-meshheading:12114417-Humans, pubmed-meshheading:12114417-Leukemia, Myelogenous, Chronic, BCR-ABL Positive, pubmed-meshheading:12114417-Male, pubmed-meshheading:12114417-Middle Aged, pubmed-meshheading:12114417-Piperazines, pubmed-meshheading:12114417-Prognosis, pubmed-meshheading:12114417-Protein-Tyrosine Kinases, pubmed-meshheading:12114417-Pyrimidines, pubmed-meshheading:12114417-Survival Rate, pubmed-meshheading:12114417-Treatment Outcome
pubmed:year
2002
pubmed:articleTitle
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
pubmed:affiliation
Departments of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II